{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:03:44Z","timestamp":1791407024913,"version":"4.3.3"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Better understanding the impact of social determinants of health (SDOH) barriers from the patient perspective is crucial to improve holistic patient support in generalized myasthenia gravis (gMG), a rare autoimmune disorder with high disease and treatment burden. The objective of this study was to identify economic challenges experienced by individuals living with gMG and SDOH barriers to better address current unmet needs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults (18\u201375\u2009years) living with gMG and experiencing SDOH barriers in the United States were recruited to a mixed-methods study including qualitative interviews and a web-based quantitative survey. Quotas were implemented to include a balanced spread of baseline demographic categories including insurance type, living environment, and employment status among the study sample. Direct and indirect economic challenges were identified by degree of concern.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The survey was completed by 38 individuals living with gMG, the majority of whom were enrolled in public insurance and not employed. The most commonly reported major economic concerns were managing funds for emergency care (66%), loss of income (61%), and non-medical expenses (58%), highlighting the diversity of economic challenges. Individuals who were using public insurance plans, living in non-urban environments, and unemployed experienced pronounced challenges around managing non-medical costs and accessing government assistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Both direct and indirect costs were emphasized as major concerns among individuals living with gMG and SDOH barriers. Increasing access to relevant, personalized, and holistic resources, including care management, should be prioritized to improve disease management and outcomes for individuals living with gMG.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1247931","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T09:37:08Z","timestamp":1694511428000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["The economic burden of individuals living with generalized myasthenia gravis and facing social determinants of health challenges"],"prefix":"10.3389","volume":"11","author":[{"given":"Tom","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James F.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E. L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Suchotliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Guptill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"ref1","year":"2015"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/WCO.0000000000000858","article-title":"Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies","volume":"33","author":"Dalakas","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","article-title":"The epidemiology of myasthenia gravis","volume":"14","author":"Bubuioc","year":"2021","journal-title":"J Med Life"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"120268","DOI":"10.1016\/j.jns.2022.120268","article-title":"The humanistic burden of myasthenia gravis: a systematic literature review","volume":"437","author":"Gelinas","year":"2022","journal-title":"J Neurol Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/CND.0000000000000257","article-title":"Impact of refractory myasthenia gravis on health-related quality of life","volume":"20","author":"Boscoe","year":"2019","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/mus.26695","article-title":"Cross-sectional analysis of the myasthenia gravis patient registry: disability and treatment","volume":"60","author":"Cutter","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12883-022-02692-4","article-title":"A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis","volume":"22","author":"Harris","year":"2022","journal-title":"BMC Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: taking the patient's perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"J Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"822909","DOI":"10.3389\/fpubh.2022.822909","article-title":"Socio-economic burden of myasthenia gravis: a cost-of-illness study in Bulgaria","volume":"10","author":"Ignatova","year":"2022","journal-title":"Front Public Health"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00415-009-5256-6","article-title":"Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy","volume":"257","author":"Schepelmann","year":"2010","journal-title":"J Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e16367","DOI":"10.1016\/j.heliyon.2023.e16367","article-title":"Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy","volume":"9","author":"Antonini","year":"2023","journal-title":"Heliyon"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/mus.22212","article-title":"Cost analysis of myasthenia gravis from a large U.S. insurance database","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.22327","article-title":"Estimated cost of treating myasthenia gravis in an insured U.S. population","volume":"45","author":"Guptill","year":"2012","journal-title":"Muscle Nerve"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jocn.2016.11.003","article-title":"Direct and indirect cost of myasthenia gravis: a prospective study from a tertiary care teaching hospital in India","volume":"38","author":"Sonkar","year":"2017","journal-title":"J Clin Neurosci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/j.lanwpc.2020.100063","article-title":"Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study","volume":"5","author":"Chen","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000311012","article-title":"Nationwide population-based epidemiological study of myasthenia gravis in Taiwan","volume":"35","author":"Lai","year":"2010","journal-title":"Neuroepidemiology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1213\/ANE.0000000000004239","article-title":"Effect of Sugammadex on postoperative Myasthenic crisis in myasthenia gravis patients: propensity score analysis of a Japanese Nationwide database","volume":"130","author":"Mouri","year":"2020","journal-title":"Anesth Analg"},{"key":"ref20","first-page":"286","article-title":"Prevalence of factors associated with poor outcomes of hospitalized myasthenia gravis patients in Thailand","volume":"19","author":"Tiamkao","year":"2014","journal-title":"Neurosciences (Riyadh)"},{"key":"ref21","year":"2013"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1590\/S0124-00642012000200007","article-title":"The cost-effectiveness of open or thoracoscopic thymectomy compared to medical treatment in managing myasthenia gravis without thymomas","volume":"14","author":"Chicaiza-Becerra","year":"2012","journal-title":"Rev Salud Publica"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/mus.25624","article-title":"Inpatient cost analysis for treatment of myasthenia gravis","volume":"56","author":"Omorodion","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"809999","DOI":"10.3389\/fneur.2021.809999","article-title":"Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia gravis in the United States","volume":"12","author":"Phillips","year":"2021","journal-title":"Front Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/mus.24960","article-title":"Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis","volume":"53","author":"Furlan","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ijcard.2019.09.054","article-title":"Burden and impact of takotsubo syndrome in myasthenic crisis: a national inpatient perspective on the under-recognized but potentially fatal association","volume":"299","author":"Desai","year":"2020","journal-title":"Int J Cardiol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"120531","DOI":"10.1016\/j.jns.2022.120531","article-title":"A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment","volume":"445","author":"Ting","year":"2023","journal-title":"J Neurol Sci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","article-title":"Economic costs of myasthenia gravis: a systematic review","volume":"38","author":"Landfeldt","year":"2020","journal-title":"PharmacoEconomics"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","article-title":"Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis","volume":"18","author":"Dalakas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12883-016-0757-2","article-title":"Labour market participation and sick leave among patients diagnosed with myasthenia gravis in Denmark 1997-2011: a Danish nationwide cohort study","volume":"16","author":"Frost","year":"2016","journal-title":"BMC Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jocn.2015.01.022","article-title":"Clinical features and impact of myasthenia gravis disease in Australian patients","volume":"22","author":"Blum","year":"2015","journal-title":"J Clin Neurosci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40120-022-00408-x","article-title":"Understanding the symptom burden and impact of myasthenia gravis from the Patient's perspective: a qualitative study","volume":"12","author":"Jackson","year":"2023","journal-title":"Neurol Ther"},{"key":"ref35","year":"2022"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/00333549131286s301","article-title":"From theory to action: applying social determinants of health to public health practice","volume":"128","author":"Dean","year":"2013","journal-title":"Public Health Rep"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jcjd.2022.05.012","article-title":"Underrepresented voices: impacts of social determinants of health on type 1 diabetes family management in single-parent, black families","volume":"46","author":"Morone","year":"2022","journal-title":"Can J Diabetes"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13690-022-00987-z","article-title":"Unfavorable social determinants of health are associated with higher burden of financial toxicity among patients with atherosclerotic cardiovascular disease in the US: findings from the national health interview survey","volume":"80","author":"Valero-Elizondo","year":"2022","journal-title":"Arch Public Health"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dci20-0053","article-title":"Social determinants of health and diabetes: a scientific review","volume":"44","author":"Hill-Briggs","year":"2020","journal-title":"Diabetes Care"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"8c","DOI":"10.1016\/s0828-282x(10)71075-8","article-title":"The impact of social determinants on cardiovascular disease","volume":"26","author":"Kreatsoulas","year":"2010","journal-title":"Can J Cardiol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.sapharm.2020.08.011","article-title":"Research with youth of color in low-income communities: strategies for recruiting and retaining participants","volume":"17","author":"Mendelson","year":"2021","journal-title":"Res Soc Adm Pharm"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1147489","DOI":"10.3389\/fpubh.2023.1147489","article-title":"Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programs","volume":"11","author":"Hughes","year":"2023","journal-title":"Front Public Health"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13023-019-1289-9","article-title":"Out-of-pocket expenses for myasthenia gravis patients in China: a study on patients insured by basic medical insurance in China, 2013-2015","volume":"15","author":"Lin","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1756286419832242","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/mus.26694","article-title":"Employment in refractory myasthenia gravis: a Myasthenia Gravis Foundation of America registry analysis","volume":"60","author":"Harris","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e013278","DOI":"10.1136\/bmjopen-2016-013278","article-title":"Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study","volume":"7","author":"Nagane","year":"2017","journal-title":"BMJ Open"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10072-020-04528-w","article-title":"Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis","volume":"42","author":"Vitturi","year":"2021","journal-title":"Neurol Sci"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000506310","article-title":"Employment in myasthenia gravis: a systematic literature review and meta-analysis","volume":"54","author":"Guastafierro","year":"2020","journal-title":"Neuroepidemiology"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s13760-019-01102-w","article-title":"A study of comorbidities in myasthenia gravis","volume":"120","author":"Misra","year":"2020","journal-title":"Acta Neurol Belg"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4172\/2155-9562.1000317","article-title":"Myasthenia gravis and its comorbidities","volume":"6","author":"Cacho Diaz","year":"2015","journal-title":"J Neurol Neurophysiol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1016\/j.amepre.2021.12.002","article-title":"Social needs resource connections: a systematic review of barriers, facilitators, and evaluation","volume":"62","author":"Steeves-Reece","year":"2022","journal-title":"Am J Prev Med"},{"key":"ref52","year":"2022"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1089\/pop.2010.0032","article-title":"The impact of a proactive chronic care management program on hospital admission rates in a German health insurance society","volume":"13","author":"Hamar","year":"2010","journal-title":"Popul Health Manag"},{"key":"ref54","year":"2023"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e184273","DOI":"10.1001\/jamanetworkopen.2018.4273","article-title":"Association of a care coordination model with health care costs and utilization: the Johns Hopkins Community health partnership (J-CHiP)","volume":"1","author":"Berkowitz","year":"2018","journal-title":"JAMA Netw Open"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.37765\/ajmc.2022.89186","article-title":"Cost-effectiveness of case management: a systematic review","volume":"28","author":"Klaehn","year":"2022","journal-title":"Am J Manag Care"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/NCM.0000000000000608","article-title":"Development of a long-term cross-sectoral case and care management manual for patients with severe multiple sclerosis and their caregivers","volume":"28","author":"M\u00fcller","year":"2023","journal-title":"Prof Case Manag"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"e049300","DOI":"10.1136\/bmjopen-2021-049300","article-title":"Communication, coordination, and security for people with multiple sclerosis (COCOS-MS): a randomised phase II clinical trial protocol","volume":"12","author":"Golla","year":"2022","journal-title":"BMJ Open"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1370\/afm.2233","article-title":"Case management in primary care for frequent users of health care services: a mixed methods study","volume":"16","author":"Hudon","year":"2018","journal-title":"Ann Fam Med"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/NCQ.0000000000000040","article-title":"Outcomes of a quality improvement project implementing stroke discharge advocacy to reduce 30-day readmission rates","volume":"29","author":"Poston","year":"2014","journal-title":"J Nurs Care Qual"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1161\/STROKEAHA.115.012524","article-title":"Reducing readmissions after stroke with a structured nurse practitioner\/registered nurse transitional stroke program","volume":"47","author":"Condon","year":"2016","journal-title":"Stroke"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1161\/STROKEAHA.122.037451","article-title":"Stroke care costs and cost-effectiveness to inform health policy","volume":"53","author":"Bettger","year":"2022","journal-title":"Stroke"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/MLR.0000000000001462","article-title":"The cost of implementing and sustaining the COMprehensive post-acute stroke services model","volume":"59","author":"Bayliss","year":"2021","journal-title":"Med Care"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"e9184","DOI":"10.7759\/cureus.9184","article-title":"A review of psychiatric comorbidity in myasthenia gravis","volume":"12","author":"Law","year":"2020","journal-title":"Cureus"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1111\/hex.13539","article-title":"The role of advocacy and empowerment in shaping service development for families raising children with developmental disabilities","volume":"25","author":"Szlamka","year":"2022","journal-title":"Health Expect"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000513867","article-title":"Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere","volume":"145","author":"Kalantar-Zadeh","year":"2021","journal-title":"Nephron"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12939-023-01841-6","article-title":"Interventions to reduce cancer screening inequities: the perspective and role of patients, advocacy groups, and empowerment organizations","volume":"22","author":"Richardson-Parry","year":"2023","journal-title":"Int J Equity Health"},{"key":"ref68","year":"2010"},{"key":"ref69","year":"2010"},{"key":"ref70","year":"2018"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1247931\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T09:37:11Z","timestamp":1694511431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1247931\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":70,"alternative-id":["10.3389\/fpubh.2023.1247931"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1247931","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"article-number":"1247931"}}